The total return over the past 12 months is -83.29% vs. +16.94% for the S&P 500. So far it's up -53.65% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (83.29%) | (36.38%) | (37.74%) | (7.93%) | (8.37%) | (8.71%) |
| Total Return CAGR | (83.29%) | (36.38%) | (37.74%) | (7.93%) | (8.37%) | (8.71%) |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Anavex Life Sciences Corp. (AVXL)
| Year | Start price | End price | AVXL Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $3.56 | $1.65 | (53.65%) | +14.51% | (68.16%) |
| 2025 | $10.74 | $3.56 | (66.85%) | +17.72% | (84.57%) |
| 2024 | $9.31 | $10.74 | +15.36% | +24.89% | (9.53%) |
| 2023 | $9.26 | $9.31 | +0.54% | +26.19% | (25.65%) |
| 2022 | $17.34 | $9.26 | (46.60%) | (18.17%) | (28.43%) |
| 2021 | $5.40 | $17.34 | +221.11% | +28.74% | +192.37% |
| 2020 | $2.59 | $5.40 | +108.49% | +18.37% | +90.12% |
| 2019 | $1.56 | $2.59 | +66.03% | +31.22% | +34.81% |
| 2018 | $3.22 | $1.56 | (51.55%) | (4.56%) | (46.99%) |
| 2017 | $3.96 | $3.22 | (18.69%) | +21.70% | (40.39%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
